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Abstract
Background: Copper oxide (CuO) nanomaterials are used in a wide range of industrial and commercial applications.
These materials can be hazardous, especially if they are inhaled. As a result, the pulmonary effects of CuO
nanomaterials have been studied in healthy subjects but limited knowledge exists today about their effects
on lungs with allergic airway inflammation (AAI). The objective of this study was to investigate how pristine
CuO modulates allergic lung inflammation and whether surface modifications can influence its reactivity.
CuO and its carboxylated (CuO COOH), methylaminated (CuO NH3) and PEGylated (CuO PEG) derivatives were
administered here on four consecutive days via oropharyngeal aspiration in a mouse model of AAI. Standard
genome-wide gene expression profiling as well as conventional histopathological and immunological methods
were used to investigate the modulatory effects of the nanomaterials on both healthy and compromised
immune system.
Results: Our data demonstrates that although CuO materials did not considerably influence hallmarks of
allergic airway inflammation, the materials exacerbated the existing lung inflammation by eliciting dramatic
pulmonary neutrophilia. Transcriptomic analysis showed that CuO, CuO COOH and CuO NH3 commonly
enriched neutrophil-related biological processes, especially in healthy mice. In sharp contrast, CuO PEG had a
significantly lower potential in triggering changes in lungs of healthy and allergic mice revealing that surface
PEGylation suppresses the effects triggered by the pristine material.
Conclusions: CuO as well as its functionalized forms worsen allergic airway inflammation by causing neutrophilia in
the lungs, however, our results also show that surface PEGylation can be a promising approach for inhibiting the
effects of pristine CuO. Our study provides information for health and safety assessment of modified CuO materials,
and it can be useful in the development of nanomedical applications.
Keywords: CuO, Engineered nanomaterial, Health effects, Inflammation, Asthma, Allergic airway inflammation, Risk
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Background
Nanotechnology is a rapidly expanding field of material
manipulation. It focuses on improving physicochemical
characteristics of different materials and thereby offers
numerous possibilities for product development in sev-
eral industrial sectors. Metal oxides are one of the most
abundantly produced types of engineered nanomaterials
(ENM) with production volumes of up to thousands of
tons every year [1]. CuO nanomaterials are appealing
due to their electrical, optical, magnetic and biocidal fea-
tures, thus they are produced for variety of industrial
and commercial applications, such as electronic chips,
solar cells, lithium batteries, paints, processed wood and
plastics [2–4]. Because of their antimicrobial properties,
CuO nanomaterials are used or could be utilized in food
packaging, wound dressings, skin products and textiles
[2–4]. An important innovation in health care is CuO-
containing bed sheets that reduce the occurrence of
hospital-acquired infections and thus decrease health
care costs in medical facilities [4]. In addition, CuO
ENM can be potentially used in nanomedicine as anti-
cancer and bioimaging agents [5, 6].
Asthma is a pulmonary disease that affects over 330
million people worldwide and its prevalence is rising
rapidly [7]. It is characterized by chronic airway inflam-
mation, reoccurring episodes of airway obstruction, air-
way hyperresponsiveness (AHR), mucus overproduction
and airway remodeling [8, 9]. Asthma has multiple forms
and it can be caused by several environmental factors in
combination with over 100 susceptibility genes [8]. The
extrinsic phenotype (also known as allergic or atopic
asthma) starts early on in life and is triggered by an al-
lergen, such as pollen or pet dander. Another pathway
of asthma (intrinsic, non-allergic) is independent of Th2
cells and adaptive immunity but relies on the presence
of neutrophils and IL-17, which is a neutrophilic chemo-
tactic factor. This “neutrophilic asthma” is associated
with nonallergic stimuli, such as cigarette smoke, cold
air or pollutants. Pulmonary neutrophilic inflammation
is also a major characteristic of patients with severe,
steroid non-responding asthma [8–10].
The most common phenotype of asthma found in chil-
dren and half of adults is atopic in nature [11]. The clas-
sical asthmatic response can be divided into early and
late phase reactions. During the immediate, early phase
response, antigen contact causes local mast cell activa-
tion and release of their mediators that ultimately culmi-
nates in an acute asthmatic attack. The late-phase
response arrives several hours later and can last for pro-
longed periods of time [12]. Pathomechanistically, the al-
lergens cause a complex immune response that starts
with the activation and differentiation of allergen-
specific CD4+ T helper (Th) 2 cells. Th2 lymphocytes
mediate their functions by releasing Th2 cytokines IL-4,
IL-5, and IL-13 [11]. IL-4 switches B-cell antibody pro-
duction to IgE that subsequently activates the high-
affinity IgE receptor FcεRI-carrying mast cells, eosino-
phils and basophils. IL-5 recruits eosinophils into the
lungs and IL-13 triggers AHR and mucus hyperproduc-
tion which are classical hallmarks of allergic asthma [9].
As for many nanomaterials, inhalation is one of the
most significant routes of CuO exposure. Pulmonary ex-
posure to CuO nanomaterials has been investigated pre-
viously in healthy subjects [13, 14], but there is only
limited information about the effects of the material on
asthma as well as on allergic airway inflammation (AAI)
– a condition preceding the chronic disease [2]. Using a
mouse model of ovalbumin (OVA)-induced AAI (Add-
itional file 5: Figure S1), the aim of this study was to in-
vestigate the adverse effects of nano-sized core CuO
(CuO) on the pulmonary condition, and to understand
whether the carboxylated (CuO COOH), methylami-
nated (CuO NH3) and PEGylated (CuO PEG) derivates
of CuO influence its reactivity.
Results
Particle characterisation and the total measured copper
content in the test materials
The total measured Cu concentration in the original
powders of the different test materials is presented in
Table 1, along with the details of purity, primary particle
size, surface area and zeta potential of the materials in-
vestigated. On a mass basis of each material, the Cu con-
tent of each material varied according to the proportion
of mass attributed to the coating. Consequently, less
total Cu was measured in the coated ENMs relative to
the uncoated form (Table 1). For the coated CuO NPs,
the NH4
+-coated NPs were found to contain the highest
measured fraction of Cu (0.52), followed by the COOH-
coated NPs (0.43) and least Cu in the PEG-coated NPs
(0.29). Example images of the nanomaterials with par-
ticle size distributions of dispersions measured by nano-
particle tracking analysis are shown in Additional file 6:
Figure S2 and Additional file 7: Figure S3. The primary
particle sizes of the powders, as measured by transmis-
sion electron microscopy (TEM), did not exceed the
manufacturer’s reported size range (10–20 nm). Follow-
ing dispersion of the test materials in ultrapure water,
the mean hydrodynamic diameters of the aggregates
were measured by nanoparticle tracking analysis, and
were: 41 nm in the uncoated CuO NPs, 46 nm in the
ammonium-coated CuO NPs, 121 nm in the COOH-
coated CuO NPs and 100 nm in the PEG-coated CuO
NPs (Table 1). Similar sizes of aggregates were formed for
the respective particles in Krebs physiological saline (Table
1). The dialysis experiments revealed some Cu dissolution
from the different CuO NPs in ultrapure water. The dialy-
sis curves are shown in Additional file 8: Figure S4. The
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Fig. 1 (See legend on next page.)
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dissolution rate of the uncoated CuO NPs was low
(1.68 μg Cu h− 1, Table 1), but in comparison, all the
coated CuO NPs had higher dissolution rates; greater than
18 μg Cu h− 1 in ultrapure water (Table 1). However, the
rates were still micromolar, and even the highest rates
would only equate to maximally around 6–9% of the total
metal being released every hour in water. The dissolution
rates for the ENM in Krebs physiological saline were much
lower than the equivalent material in ultrapure water (Table
1), and represented less than 3% of metal being released in
an hour. Thus, it is expected that the materials will remain
in particulate form in physiological saline over 24 h.
Exposure to CuO nanomaterials induced significant
neutrophil migration into the lungs of phosphate-
buffered saline (PBS)- and OVA-challenged mice
To characterize the pulmonary effects of CuO materials,
inflammatory cell influx in bronchoalveolar lavage (BAL)
and pathological changes in lung tissue were evaluated
along with mRNA expression analysis of cytokines in
tissue samples. Development of AAI in our model was
evidenced by increased number of eosinophils and lym-
phocytes in BAL, activation of goblet cells in lung tissue
and up-regulation of pro-inflammatory TNF, pro-allergic
IL-33 and Th2 type IL-13 in the lungs of OVA-
challenged compared with PBS-challenged mice (OVA
versus PBS group in Fig. 1). Furthermore, OVA-
challenged mice exhibited eosinophils as well as elevated
number of CD4+ T cells in the lung tissue (OVA versus
PBS in Fig. 2a-b, e).
CuO materials tested in our study induced a significant
neutrophil influx into the airways of PBS- as well as OVA-
challenged mice (Fig. 1a). The materials did not influence
the number of eosinophils in BAL nor mucus-producing
goblet cells in the lung tissue of OVA-challenged mice,
except in case of CuO NH3 whose exposure triggered
additional migration of eosinophils into the airways (Fig.
1a-b). Co-exposure to OVA and CuO materials had an
additive (mostly dose-dependent) effect on the number of
macrophages and lymphocytes (Fig. 1a). Total number of
BAL cells and relative proportion of differential immune
cells is presented in Additional file 1: Table S1.
CuO nanomaterials increased the expression of pro-
inflammatory TNF and pro-allergic IL-33 but did not
up-regulate IL-13 expression in PBS-challenged mice, as
compared to specific controls (Fig. 1c). TNF and IL-33
levels were increased especially in response to CuO in
both PBS-challenged as well as OVA-challenged in mice.
In OVA-challenged mice, CuO nanomaterials rather
suppressed the expression of IL-13 compared with OVA
controls (Fig. 1c). IL-13 was measured also at the protein
level in BAL supernatants and no significant changes
were seen in OVA-challenged groups, except in a case of
CuO NH3 that had increased IL-13 protein release at
doses 2.5 and 10 μg/mouse (Fig. 1d).
Histological assessment of mice treated with CuO nano-
materials, revealed the presence of inflammatory areas
and nuclear dust (Fig. 2a-d; Additional file 9: Figure S5).
These changes were seen in both PBS- and OVA-
challenged mice treated with 10 and 40 μg/mouse of CuO,
CuO COOH and CuO NH3. Inflammation was milder at
10 μg/mouse in CuO PEG-exposed mice (Additional file 9:
Figure S5A) whereas the effects were comparable to the
ones of other CuO materials at 40 μg/mouse. Nuclear dust
was especially evident in the lung tissue at the highest
dose of 40 μg/mouse, at which it was observed in response
to all ENM (Fig. 2c-d). Since all materials exhibited similar
changes at the highest dose, quantification of the inflam-
matory areas and nuclear dust was performed at dose
10 μg/mouse. The core material and CuO PEG only were
selected for evaluation because the other surface-
functionalized materials had equivalent effects on the lung
tissue at this dose as CuO. It was found that exposure to
CuO triggered or enhanced inflammation and caused the
formation of nuclear dust in both OVA- and PBS-
challenged mice as compared with their respective con-
trols (Additional file 9: Figure S5B). CuO PEG-induced in-
flammation in PBS-challenged mice was minor compared
with PBS controls and significantly milder compared to
the inflammation caused by CuO. Similar result appeared
also in OVA-challenged mice but the difference between
the groups of CuO and CuO PEG was statistically insig-
nificant. Nuclear dust was observed only in CuO- but not
in CuO PEG-treated mice (Additional file 9: Figure S5C).
(See figure on previous page.)
Fig. 1 Cell counts, expression and release of (pro-)inflammatory markers following exposure to CuO materials. BALB/c mice were sensitized ip to
OVA/Alum on day 1 and 10, and exposed repeatedly to 2.5, 10 or 40 μg/mouse of CuO nanomaterials dispersed in PBS with or without OVA by
oropharyngeal aspiration after a 10-day recovery period. a BAL cell counts showed the ability of CuO materials to trigger an increase in the
number of macrophages, lymphocytes and especially neutrophils into the airways of both PBS- and OVA-challenged mice whereas eosinophils
were detected only in OVA-challenged groups. b PAS staining revealed that CuO materials did not activate mucin-production in goblet cells. c
Pro-inflammatory cytokines TNF and IL-33 were expressed in PBS-challenged as well as OVA-challenged mice while Th2 type cytokine IL-13 was
expressed only in OVA-challenged mice. d IL-13 protein was detected in BAL supernatants by ELISA also only in OVA-challenged mice. Results in
a-b are shown with the highest number of cells marked on top of each plot. Columns and error bars represent mean values ± standard error of
mean (SEM). Statistically significant differences between experimental groups and PBS-challenged control mice are marked with “*” whereas the
ones between experimental groups and OVA-challenged control mice are marked with “•”. */•P < 0.05; **/••P < 0.01; ***/•••P < 0.001. HPF, high
power field; PAS, periodic acid–Schiff
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Fig. 2 (See legend on next page.)
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Immunohistochemical staining of lung tissue revealed no
increased influx of T cell subtypes in PBS-challenged mice.
However, increase of CD3+ T cells in OVA-challenged
mice was seen after treatment with all CuO materials, es-
pecially at the dose of 10 μg/mouse, except with CuO PEG
(Fig. 2e). Further characterization showed that this increase
was derived from the elevated presence of CD4+ T cells
since the numbers of CD8+ T cells remained generally at
similar levels as in OVA-challenged mice.
Transcriptome analysis revealed that CuO PEG has a
lower potential in triggering changes at gene expression
level than other tested materials
Hierarchical clustering of top 500 differentially expressed
genes (DEGs) showed that lung tissue of PBS-challenged
mice exposed to the two lower doses (2.5 and 10 μg/
mouse) of CuO PEG shared similar expression patterns
with their controls (cluster e in Fig. 3a). The same trend
was also seen among OVA-challenged mice (cluster a in
Fig. 3a). Samples from mice treated with lower doses of
all other materials and the highest dose of CuO PEG
clustered together within both, PBS-challenged and
OVA-challenged mice (clusters b-c in Fig. 3a). Regard-
less of the allergen challenge, mice exposed to higher
doses of all materials except CuO PEG shared a similar
expression pattern (cluster d in Fig. 3a).
Number of DEGs in each experimental group com-
pared with their respective controls revealed that more
changes took place in PBS-challenged than in OVA-
challenged mice (Fig. 3b, Additional file 2: Table S2).
Every material triggered a dose-dependent response as
the number of DEGs was increasing across the doses.
CuO PEG induced notably less changes compared with
other CuO materials which supports the finding seen on
the heatmap. Venn comparisons of DEG sets of experi-
mental groups revealed that the highest number of
DEGs were exclusive or shared between higher doses of
CuO, CuO COOH and CuO NH3 in both PBS-
challenged and OVA-challenged mice (Fig. 3c).
To validate the microarray data, monocyte chemoat-
tractants CCL2 (MCP-1) and CCL7 (MCP-3), and
eosinophil-recruiting CCL11 (eotaxin-1) were chosen for
reanalysis by real-time quantitative polymerase chain
reaction (PCR). The PCR-based expression levels were
highly correlating (Pearson’s r ≥ 0.95) with the tran-
scriptomics data (Additional file 10: Figure S6). Further-
more, CCL2 was measured at protein level in BAL
supernatants and its levels were highly similar to those
obtained by microarray and PCR. In addition, several
biomarkers linked to AAI were also identified in the
microarray-based transcriptomics data to present the
differences between PBS- and OVA-challenged control
mice (Additional file 11: Figure S7).
Irrespective of differentiating transcriptome profiles, CuO,
CuO COOH and CuO NH3 displayed commonalities at
pathway level
Excluding dose as a variable, we combined experimental
groups of PBS-challenged or OVA-challenged mice that
were treated with the same CuO material and compared
their transcriptomic profiles against the ones of their
corresponding controls to explore general differences
between the materials at gene expression level (Fig. 4,
Additional file 12: Figure S8, Additional file 3: Table S3).
CuO PEG did not produce any DEGs in mice challenged
with PBS or OVA, while the other three materials elic-
ited specific transcriptomic changes in both phenotypes.
In PBS-challenged mice, 7.9, 13.2 and 39.9% of the
DEGs were identified as unique to CuO, CuO COOH
and CuO NH3 respectively, while 14.2% of the DEGs
were shared between all three materials (Fig. 4a). A simi-
lar trend – where the most unique transcriptomic re-
sponses originated from CuO NH3 – was also observed
in transcriptome of OVA-challenged mice (Add-
itional file 12: Figure S8), but no functionally (in)acti-
vated biological processes could be identified based on
Ingenuity™ pathway analysis (IPA) [16]. On the other
hand, in PBS-challenged mice, the material-type-specific
DEGs were predicted to activate/inactivate several path-
ways where the extent of activation/deactivation varied
according to the material surface chemistry (Fig. 4b). All
three materials suppressed Cell Cycle at G2/M DNA
Damage Checkpoint Regulation and Antioxidant Action
of Vitamin C pathway, for which the lowest degree of in-
hibition was predicted for core CuO DEGs. Similar
surface-chemistry-based bioreactivity was also observed
(See figure on previous page.)
Fig. 2 Histological and immunohistochemical evaluation of the lung tissue after exposure to CuO nanomaterials. BALB/c mice were sensitized ip
to OVA/Alum on day 1 and 10, and exposed repeatedly to 2.5, 10 or 40 μg/mouse of CuO nanomaterials dispersed in PBS with or without OVA
by oropharyngeal aspiration after a 10-day recovery period. H&E-stained lung tissue of a a PBS-challenged control, b OVA-challenged, c PBS-
challenged and 40 μg of core CuO-exposed, and d OVA-challenged and 40 μg of core CuO-exposed mouse. The presence of eosinophils in OVA-
challenged mice and neutrophils accompanied with nuclear dust in CuO-treated mice were found. E, The number of CD3+, CD4+ and CD8+ T
cells in the lung tissue. Images a-d are shown at × 400 magnification with a 50-μm scale bar. Arrows in the insets indicate the location of nuclear
dust. Counts of T cell subtypes in e are shown as positive cells per high power field (HPF) with the highest number of cells marked on top of
each plot. Columns and error bars represent mean values ± standard error of mean (SEM). Statistically significant differences between
experimental groups and PBS-challenged control mice are marked with “*” whereas the ones between experimental groups and OVA-challenged
control mice are marked with “•”. */•P < 0.05; ***/•••P < 0.001
Ilves et al. Particle and Fibre Toxicology           (2019) 16:28 Page 7 of 21
for the predicted activation of several innate immunity
and pro-inflammatory pathways (Fig. 4b; IPA compari-
son analysis). Among others, Aryl Hydrocarbon Recep-
tor Signaling (least activated by core CuO) and
Dendritic Cell Maturation pathways (least activated by
CuO NH3) were activated.
To study similarities of the biological processes,
EnrichR tool was used [17, 18]. In PBS-challenged mice,
17 processes were commonly enriched in response to
CuO, CuO COOH and CuO NH3 (Fig. 4c). Majority of
these were related to cytokine/chemokine signaling, but
other inflammatory processes, such as macrophage and
Fig. 3 Differential gene expression analysis. a Heat map of top 500 differentially expressed genes (linear FC > |1.5|, adjusted P value < 0.05) in
each analyzed lung tissue sample of PBS- and OVA-challenged mice exposed to CuO nanomaterials by oropharyngeal aspiration (2.5, 10 and
40 μg/mouse). Z-score normalized log2 intensity values were used as input for hierarchical clustering. Red color indicates a higher expression
while green refers to a lower expression. b Numbers of total, up-regulated, down-regulated and exclusively differentially expressed genes (DEGs;
linear FC > |1.5|, adjusted P value < 0.05) in lung tissue after exposure to CuO nanomaterials of PBS- and OVA-challenged mice versus the
corresponding control mice. c UpSet plots showing 20 largest intersections of DEGs that are either specific to a treatment or shared between
experimental groups among PBS and OVA-challenged mice. The upper bar chart indicates the number of DEGs in each intersection
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neutrophil chemotaxis, and cell division overlapped be-
tween the materials as well (Fig. 4d). In OVA-challenged
mice, only few DEGs were obtained (Additional file 12:
Figure S8A), however, enrichment analysis revealed one
common biological process, i.e. neutrophil degranulation
(Additional file 12: Figure S8B) that was seen also in
PBS-challenged mice.
PEGylation modulates bioreactivity of pristine CuO via
predicted suppression of inflammatory pathways
To investigate how surface functionalization affects the
effects of core CuO, each dose of every modified mater-
ial was compared against the corresponding dose of core
CuO (Fig. 5, Additional file 4: Table S4). Numbers of
DEGs showed that CuO COOH and CuO NH3 triggered
notably less changes than CuO PEG at all doses. Enrich-
ment analysis by PANTHER [19] revealed that DEGs of
CuO COOH and CuO NH3 groups resulted in none or
few significantly enriched biological processes (Fig. 5a).
In contrast, a large number of biological processes were
enriched by the set of DEGs in treatment groups of CuO
PEG. Therefore, CuO PEG was chosen for further ana-
lysis to understand how the surface modification alters
the effect of the core material.
Up- and down-regulated genes derived from CuO
PEG groups were analyzed separately. It was found that
Fig. 4 General profiling of canonical pathways and biological processes in PBS-challenged mice after CuO, CuO COOH and CuO NH3 exposure.
Experimental groups of exposed PBS-challenged mice were merged based on the test material, and their transcriptomic profiles were compared
against the one of PBS-challenged controls. a A Venn distribution of the number of DEGs (linear FC > |1.5|, adjusted P value < 0.05) in lungs of
PBS-challenged mice exposed to CuO nanomaterials by oropharyngeal aspiration (2.5, 10 and 40 μg/mouse). b A heat map showing the
activation z-scores of IPA canonical pathways filtered with z-score > 2 and -log(P value) > 2 across the materials. c Venn comparison of
significantly enriched biological processes (adjusted P value < 0.05) obtained from analyses of DEG sets shown in (a). d 17 biological processes
were commonly enriched by DEGs from the CuO, CuO COOH and CuO NH3 exposures
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Fig. 5 (See legend on next page.)
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in PBS-challenged mice at the lowest dose of 2.5 μg/
mouse, only down-regulated genes resulted in significantly
enriched biological processes. Majority of these processes
categorized under inflammatory response, cell and nuclear
division, positive regulations of immune system process
and regulation of cytokine production (Additional file 13:
Figure S9). Causal analysis using IPA’s Ingenuity Know-
ledge Base further confirmed that the down-regulated
genes predictively suppress several innate immunity and
pro-inflammatory pathways (Fig. 5b; dose 2.5 μg/mouse).
In contrast, immune system related processes such as
leucocyte activation, cytokine production, positive regula-
tion of cell-cell adhesion and immune system process
were significantly enriched by up-regulated genes of CuO
PEG at the highest dose (40 μg/mouse) (Additional file 14:
Figure S10A). Down-regulated genes enriched processes
belonging to negative regulation of peptidase activity, mi-
totic cell cycle, nuclear division, response to wounding
and positive regulation of cell proliferation (Add-
itional file 14: Figure S10B). Enriched inflammatory pro-
cesses represented by the up-regulated genes in OVA-
challenged mice exposed to the highest dose of CuO PEG
were inflammatory response, leucocyte activation, im-
mune system process and positive regulation of cytokine
production (Additional file 15: Figure S11). Furthermore,
IPA causal analysis indicated that the direction of gene ex-
pression change was consistent with activation of these ca-
nonical pathways (Fig. 5c; dose 40 μg/mouse).
Activation of pathways affected by CuO materials was
more distinguishable in PBS-challenged than in OVA-
challenges mice
To understand how CuO materials modulate OVA-
induced AAI, DEG sets of PBS-challenged mice were
compared to the ones of OVA-challenged mice. Overlaps
of DEGs were minor at the lowest concentration for all
materials, however, majority of the DEGs in OVA-
challenged groups were present also in PBS-challenged
mice (Additional file 16: Figure S12A). Hierarchical clus-
tering of canonical pathways revealed two main clusters:
groups of PBS- and OVA-challenged mice exposed to
lower doses (2.5 and 10 μg/mouse) of all CuO materials
and to the highest dose (40 μg/mouse) of CuO PEG, and
groups of PBS- and OVA-challenged mice treated with
the highest dose of all materials except CuO PEG (Add-
itional file 16: Figure S12B). Majority of the pathways in
OVA-challenged mice that were exposed to lower doses
of CuO materials, were unenriched or did not obtain an
activation score due to low number of DEGs. A subclus-
ter of canonical pathways related to T cell regulation
(Th1 and Th2 Pathway, CD28 Signaling in T Helper
Cells, PKC Signaling in T Lymphocytes, iCOS-iCOSL
Signaling in T Helper Cells and Calcium-induced T
Lymphocyte Apoptosis) were non-activated or slightly
up-regulated at lower doses of materials in PBS-
challenged mice while at the higher dose, these pathways
were commonly suppressed regardless of the disease sta-
tus (Additional file 16: Figure S12B).
With the exception of OVA-challenged mice treated
with lower doses of the ENM, administration of CuO
materials suppressed cell cycle in G2/M DNA damage
checkpoint. Other cell cycle pathways, such as Estrogen-
mediated S-phase Entry, Cyclins and Cell Cycle Regula-
tion and Mitotic Roles of Polo-Like Kinase were acti-
vated by exposure to CuO materials (Additional file 16:
Figure S12B). CuO materials activated also inflammatory
pathways (e.g. Role of PRR in Recognition of Bacteria
and Viruses, Dendritic Cell Maturation, IL-6 Signaling,
Role of IL-17F in Allergic Inflammatory Airway Dis-
eases, Aryl Hydrocarbon Receptor Signaling, and Acute
Phase Response Signaling), all of whose activation ap-
peared generally more distinguishable in PBS-challenged
mice than in OVA-challenged mice.
Pathways influenced by CuO materials do not
dramatically differ in PBS- and OVA-challenged mice
To explore whether CuO materials modulate immune
responses differently depending on the pulmonary con-
dition, activation scores of the canonical pathways
enriched in PBS- and OVA-challenged groups were
compared. Since the DEG sets of OVA-challenged mice
exposed to lower doses of CuO materials were small in
number (Additional file 16: Figure S12A) and conse-
quently did not result in pathway enrichment or were
too few for predicting their activation state (Add-
itional file 16: Figure S12B), canonical pathways enriched
in PBS- and OVA-challenged mice at the highest dose
(40 μg/mouse) were compared.
(See figure on previous page.)
Fig. 5 Modulatory effects of surface functional groups on CuO bioreactivity. As shown in (a), at each dose, the experimental group of every
functionalized material was compared against core CuO in PBS- or OVA-challenged mice. The most drastic effect was induced by PEGylation, as
seen from the Number of DEGs and enriched biological processes (a). The top canonical pathways enriched by down-regulated genes in PBS
mice exposed to 2.5 μg of CuO PEG as compared with core CuO at the same dose, or enriched by up-regulated genes in OVA-challenged mice
exposed to 40 μg of CuO PEG as compared with core CuO at the same dose are shown in (b) and (c) respectively. b-c The x-axis represents the
pathways identified. The y-axis on left shows the -log(P value) calculated based on Fisher’s exact test. Threshold level is set on a P value of 0.05.
The y-axis on right represents a ratio between a number of DEGs in a given pathway with a cut-off -log(P value) > 2, divided by total number of
genes belonging to the reference gene set of the pathway. The orange- and blue-colored bars indicate predicted pathway activation or
inhibition, respectively
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Majority of the pathways had a similar activation dir-
ection (Additional file 17: Figure S13). Acute phase re-
sponse signaling and intrinsic prothrombin activation
pathway were common among 5 most activated path-
ways after CuO, CuO COOH and CuO NH3 exposure in
both PBS- and OVA-challenged mice, whereas Calcium-
induced T Lymphocyte Apoptosis, iCOS-iCOSL Signal-
ing in T Helper Cells, Phospholipase C Signaling and
PKC Signaling in T Lymphocytes were common among
5 most inhibited pathways. Anti-correlated pathways in
PBS- versus OVA-challenged mice occurred after CuO
COOH (Dendritic Cell Maturation, Eicosanoid Signaling
and Antioxidant Action of Vitamin C) and CuO NH3
treatment (TREM1 Signaling), however, their activation
state had a z-score ≤ |2| and thus, cannot be considered
necessarily (in)activated (Additional file 17: Figure S13B-
C). DEG set of OVA-challenged mice after CuO PEG ex-
posure did not result in an activation or suppression of
any pathways, however, several pathways that were also
enriched in response to other materials, were activated
in PBS-challenged mice treated with CuO PEG (Add-
itional file 17: Figure S13D).
Discussion
CuO nanomaterials can be incorporated into several
broadly used consumer products and it is estimated that
worldwide production of CuO nanomaterials will raise
from 570 tons in 2014 to 1600 tons by the year 2025
[20]. Hazards of CuO nanomaterials in respiratory tract
have been evaluated in different in vitro systems [21–25]
as well as in healthy subjects in vivo [13, 14]. However,
there is a little knowledge about how these materials
might affect individuals with a pre-existing lung disease
[2, 10]. Furthermore, there is lack of information
whether modifying the surface of core CuO could influ-
ence their immunomodulatory potential in vivo. We
used a mouse model of AAI in which the mice were at
first sensitized intraperitoneally (ip) to a mixture of an
allergen, OVA, and an adjuvant, aluminium/magnesium
hydroxide (Alum), and after an 11-day recovery period,
challenged repeatedly with OVA. During the challenge
phase, CuO materials were administered to the mice on
4 consecutive days via oropharyngeal aspiration. Herein,
we made use of standard genome-wide gene expression
profiling, coupled with conventional histopathological
and immunological methods, to investigate the mecha-
nisms underlying the modulatory effects of CuO nano-
particles and their carboxylated, methylaminated and
PEGylated derivatives on healthy and compromised im-
mune system. The lack of parallel proteome-wide assess-
ment is a general limitation of transcriptome-based
mechanistic studies, as mRNA and protein levels may
not necessarily correlate [26]. Nonetheless, we comple-
mented mRNA profiling with gene ontology-based
enriched pathway analysis, which, though not definitive,
still provides insight into the biological processes af-
fected by the observed changes in gene expression. In
addition to the transcriptomic changes, we studied histo-
logical, cellular and humoral responses on the exposed
animals to support and reveal additional information on
nanomaterial exposure in the lungs.
Classical asthma is eosinophilic with increased number
of CD4+ Tcells that produce Th2 type cytokines [27]. Fur-
thermore, patients with asthma experience excessive
mucus secretion [28], and their sputum and BAL contain
elevated amounts of pro-inflammatory cytokines [29]. Pre-
viously conducted studies show that ENM modulate AAI
differently. Carbon nanotubes [30–33] and silica [34–36]
have been found to aggravate signs of AAI by increasing
eosinophil influx, triggering mucus hyperplasia and release
of pro-allergic cytokines and chemokines whereas expos-
ure to TiO2 [37, 38] during the allergen challenge has
been reported to diminish local allergic symptoms. In our
study, the tested CuO materials triggered a significant
neutrophil influx into the airways of PBS- as well as OVA-
challenged mice. Furthermore, we detected features simi-
lar to nuclear dust (karyorrhexis) in the lung tissue whose
presence has been related to and breakdown of leukocytes,
especially neutrophils [39]. Since neutrophils were the
predominant cell population in the lungs, the nuclear frag-
ments that we evidenced were likely neutrophil-derived.
However, eosinophil migration into the airways and acti-
vation of mucus-producing goblet cells in the lung tissue
were not affected by the nanomaterials in OVA-
challenged mice, except in case of CuO NH3 that en-
hanced the eosinophil influx. In addition, when excluding
the response of CuO, pro-allergic IL-33 remained at base-
line level. Furthermore, we found an elevated presence of
CD4+ T cells in OVA-challenged mice after the nanoma-
terial exposure. CD4+ lymphocytes producing Th2 cyto-
kines are common for extrinsic asthma phenotype,
however, as mRNA of Th2 type IL-13 was mainly sup-
pressed by the materials in our study and not significantly
changing at protein level except in response to CuO NH3,
involvement of other types of CD4+ Th lymphocytes in
responses driven by CuO nanomaterials might be possible.
For example, it has been demonstrated that exposure to
pollutant particles results in Th17-biased immunopheno-
type accompanied by airway neutrophilia [10] which are,
in fact, features of severe asthma [40, 41]. Taken together,
our data indicate that CuO nanomaterials do not dramat-
ically affect the hallmark features of allergic airway inflam-
mation, but the materials worsen it by adding another
inflammatory feature – pulmonary neutrophilia – to the
already existing condition.
To elucidate mechanisms behind the CuO-induced ef-
fects, we examined material-triggered changes in healthy
lungs and in lungs with AAI in more detail by
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transcriptomics profiling (NCBI GEO accession number
GSE122197). Hierarchical clustering of the most differ-
entially expressed genes revealed that changes in PBS-
challenged mice and OVA-challenged mice exposed to
the two lower doses (2.5 and 10 μg/mouse) of CuO PEG
shared similar expression patterns with their corre-
sponding controls (Fig. 3a). Numbers of DEGs in experi-
mental groups showed that more changes took place in
PBS-challenged than in OVA-challenged mice and the
number of DEGs increased across the doses of each ma-
terial reflecting to a dose-dependent response. CuO PEG
induced clearly less changes compared with other mate-
rials supporting the hierarchical clustering of the indi-
vidual samples. These data show that CuO PEG has
significantly lower potential in triggering changes in
both healthy and allergic lungs compared with CuO and
its two other functionalized derivates.
In order to explore general differences in the bioreac-
tivity of the materials at the molecular level, we com-
bined experimental groups of PBS-challenged or OVA-
challenged mice that were treated with the same CuO
material and compared their transcriptomic profiles
against those of their corresponding controls. CuO PEG
did not produce any DEGs in mice challenged with PBS
or OVA, however, comparison of the DEGs of the other
materials by IPA revealed that CuO materials in PBS-
challenged mice predictively suppressed Cell Cycle at
G2/M DNA Damage Checkpoint Regulation and Anti-
oxidant Action of Vitamin C pathways, and concurrently
activated several innate immunity and pro-inflammatory
pathways. Interestingly, Aryl Hydrocarbon Receptor Sig-
naling and Dendritic Cell Maturation pathways, that
were also found predictively activated, have been linked
to Th17 and IL-17A dependent immune responses and
neutrophilic inflammation in response to particulate
matter [10]. We then focused on biological processes in-
volved in the material-triggered responses and saw that
17 processes were commonly enriched by DEG sets of
CuO, CuO COOH and CuO NH3 in PBS-challenged
mice. These were mainly inflammatory processes, several
of which were related to neutrophil mobilization and ac-
tivation. For example, CXCL12 interacts with CXCR4
and affects the release of neutrophils from the bone
marrow [42], and CCL2 binds to CCR2 and plays a role
in neutrophil adherence, transmigration and activation
[43]. Rest of the processes included macrophage chemo-
taxis, regulation of TNF secretion, cell division and che-
mokine signaling pathways which were in line with IPA
results. Enrichment analysis of DEGs in OVA-challenged
mice revealed only neutrophil degranulation (seen also
in PBS-challenged mice) as a common biological process
between CuO, CuO COOH and CuO NH3. Neutrophil
degranulation followed by the release of neutrophil
extracellular traps is a defense mechanism of innate
immune system that can be induced by increased intra-
cellular Ca2+ [44, 45]. Furthermore, it is a feature of sev-
eral inflammatory diseases, like acute lung injury and
asphyxia episodes of asthma [44]. The uncovered
neutrophil-related pathways and biological processes
support histological and cytological findings as well as
CCL2 protein levels measured in BAL supernatants,
which all revealed that neutrophils play a role in CuO-
induced reactions regardless of the allergen challenge.
Having established that the material’s bioreactivity is
linked to its surface chemistry, we next sought to investi-
gate how surface functionalization modulates the effects
of core CuO. For this, each dose of every modified mater-
ial was compared against the corresponding dose of core
CuO. We found that CuO COOH and CuO NH3 trig-
gered notably less changes than CuO PEG based on the
number of DEGs. Furthermore, enrichment analysis re-
vealed a large number of biological processes specifically
in treatment groups of CuO PEG. We then explored how
surface PEGylation alters the effect of the core material.
By analyzing up- and down-regulated genes separately, we
found that at the lowest dose (2.5 μg/mouse) of CuO PEG
in PBS-challenged mice, only down-regulated genes
resulted in significantly enriched biological, especially in-
flammatory, processes and IPA showed that the down-
regulated genes predictively suppressed innate immunity
and pro-inflammatory pathways. On the contrary, im-
mune system related processes were at the highest dose
(40 μg/mouse) significantly enriched by up-regulated
genes of CuO PEG and similar trend was observed in
OVA-challenged mice. Overall, these data show that sur-
face PEGylation changes the effects induced by pristine
material the most. At the low concentration, core CuO is
activating inflammatory processes in healthy airways that
are suppressed when the material is PEGylated, whereas at
the high concentration, core CuO suppresses the inflam-
matory reactions in healthy as well as in asthmatic lungs
while PEGylation of the material inhibits it. These findings
suggest that surface PEGylation prevents the effects trig-
gered by core CuO from taking place.
Since equivalent molar doses of Cu could not be cal-
culated in this study due to uncertainty of the stoichi-
ometry and the technical challenges in measuring the
mass attributed to the coating [46], equivalent mass of
the whole material was used for dosing which resulted
in differing amounts of Cu in the administered doses of
the nanomaterials. Although it may have had an effect
on the outcome, it is very unlikely that the Cu fraction
in the materials (Table 1) was entirely responsible for
the ranking of the inflammatory response. The uncoated
CuO contained twice as much Cu metal than CuO
COOH and CuO NH3, but it was not twice as hazard-
ous. Similarly, CuO NH3 or CuO COOH had twice as
much Cu metal than CuO PEG but when comparing the
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number of neutrophils – the most dramatically changed
endpoint of this study, these ENM triggered more than
two times higher influx of the cells than CuO PEG. In
any event, ranking the inflammation by Cu content of
the materials would assume metal ion toxicity.
Earlier studies have underlined the importance of extra-
cellular and intracellular dissolution of ENM in biological
systems [47]. While significant amount of extracellularly
dissolved metal ions can contribute to material toxicity, it
has been observed that certain nano-sized metal oxides in-
cluding CuO cause adverse effects via the Trojan horse
mechanism, i.e. cellular uptake of ENM in particle form,
their lysosomal dissolution and subsequent rupture of the
lysosome which results in adverse effects such as cell
death and induction of inflammation [47–50]. In this
study, the dissolution rates of the tested CuO ENM in
physiological saline showed that the materials remain in
particulate form over 24 h. Furthermore, the minute levels
of dissolved copper detected in tested material samples,
did not reveal a clear correlation with neutrophil counts
in BAL – an endpoint which was clearly an ENM-driven
effect. Thus, we conclude that the possible extracellular
dissolution of the CuO nanomaterials does not play a
major role in the toxic response of the tested materials
and the adverse pulmonary effects are more likely trig-
gered by intracellular dissolution.
Suppressive and other beneficial properties of surface
PEGylation have been observed earlier and therefore, the
modification has found use in nanomedicine on anti-
cancer drugs for prolonging their circulation and reducing
off-target effects [51, 52]. One of the explanations for the
suppressive effects of surface PEGylation of ENM could
be that it renders the particles invisible for macrophages
[53]. For example, similar surface functionalizations that
were studied here have been investigated previously by
Rehberg et al. who explored the uptake of pristine and
coated quantum dots (QD) in post capillary venules in
mouse cremasteric tissue. The authors found that carb-
oxyl- and amine-QD were ingested by perivascular macro-
phages and/or endothelial cells whereas PEG-QD were
seen in-between endothelial cells, associated with amorph-
ous lipid-containing material [54]. It has been previously
reported that PEG inhibits cell adhesion non-specifically,
not by binding to a cell surface receptor [55]. Thus, it is
likely the coating itself, not the functional surface area or
the size of the nanomaterial and its aggregates, that hin-
ders the recognition of the PEG-coated particles. However,
differences in the uptake of the surface-modified nanoma-
terials by phagocytes may in turn lead to differences in
leucocyte trafficking and recruitment, and consequently,
differing immune responses and health outcomes. There-
fore, we speculate that surface chemistry is a significant
factor and it contributes to the development of the ENM-
induced pulmonary effects seen in our study.
To understand how CuO materials modulate OVA-
induced AAI, DEG sets of PBS-challenged mice were
compared to the ones of OVA-challenged mice by IPA.
We evidenced that a sub-cluster of T cell regulation
pathways was commonly suppressed at the highest dose
regardless of the disease status. With the exception of
OVA-challenged mice treated with lower doses of the
ENM, administration of CuO materials suppressed cell
cycle in G2/M DNA damage checkpoint. It is well
known that CuO materials produce ROS that initiate
mitochondrial-mediated apoptosis pathway and conse-
quently cause mitochondrial damage, activation of p53
and caspase 3 leading the cell to apoptotic death [56,
57]. It is also reported that metal oxide ENM abrogate
cell cycle in G2/M phase which gives the materials a po-
tential to be developed into anticancer agents [58, 59].
In contrast to arrest of G2/M phase transition, other cell
cycle pathways were activated by the exposure to CuO
materials. Expansion and renewal of cell populations,
however, are common processes in inflamed tissues and
hence their activation is expected. Exposure to CuO ma-
terials activated also several inflammatory pathways, all of
whose activation was generally more distinguishable in
PBS-challenged mice than in OVA-challenged mice.
Lower activation in OVA-challenged mice appears likely
due to an already existing inflammation in OVA-
challenged control mice against which the ENM-exposed
groups were compared with. In addition, we were inter-
ested in understanding whether CuO materials regulate
inflammation differently depending in PBS- and OVA-
challenged groups by comparing activation scores of the
canonical pathways. Consequently, majority of the path-
ways affected by CuO, CuO COOH or CuO NH3 expos-
ure had a similar activation direction in both, PBS- and
OVA-challenged mice. Overall, these data indicate that
the pathways affected by CuO materials do not differ dra-
matically between healthy and allergic lungs.
Conclusions
In this study, we evidenced that respiratory exposure to
pristine or modified CuO materials does not dramatically
influence classical signs of allergic airway inflammation,
however, the materials worsen the condition by adding an-
other inflammatory characteristic - pulmonary neutrophi-
lia, to the already existing allergic condition. Global
transcriptomic analysis of the lung tissue showed that
CuO PEG has significantly lower potential in triggering
changes in healthy and asthmatic lungs compared with
CuO and its carboxylated and methylaminated derivates.
General comparison of the materials at transcriptomics
level revealed that CuO, CuO COOH and CuO NH3 com-
monly enriched neutrophil-related biological processes,
especially in PBS-challenged mice. Further analysis of the
functionalization influence showed that PEGylation of the
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core CuO suppresses the effects triggered by the pristine
particles. Comparison of PBS- and OVA-challenged mice
revealed that pathways affected by exposure to CuO mate-
rials do not significantly differ in healthy and allergic
lungs. Furthermore, we demonstrated that the materials
affect T cell regulation, inhibit cell cycle at G2/M phase
transition and activate several inflammatory pathways.
Altogether, we found that exposure to core CuO as
well as its functionalized derivates exacerbate allergic
airway inflammation by causing neutrophilia in the
lungs. However, our results also showed that surface
PEGylation can be a promising strategy for suppressing
the adverse effects of inhaled pristine CuO. The data of
this study provide information for health and safety as-
sessment of modified CuO materials. Moreover, the
knowledge can be useful in the development of CuO-
based nanomedical applications.
Methods
Characterization of nanomaterials
The nanomaterials used in the present study have been
extensively characterised in ultrapure water and bio-
logical media, and for extractable fractions of Cu metal
in gut salines [15, 46, 60]. Briefly, the characterisation
followed Vassallo et al. with additional measurements in
a representative physiological saline (Krebs saline, in
mmol l− 1: NaCl, 118.6; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.2;
KH2PO4, 1.2; NaHCO3, 25.1; Glucose, 10.0; HEPES,
10.0, and at pH 7.4) [15]. The nanomaterials included
the uncoated CuO ENM, and those coated with –NH4
+,
−COOH or –PEG respectively. The precise details of
how the coatings were synthesised and attached to the
ENM core is commercially sensitive information of the
suppliers, but for clarity we use the term ‘–NH4
+’ to
mean an –NH3 terminal ligand that has been ionised
with H+ ions to achieve positive charge. The CuO ENMs
were provided by PlasmaChem GmbH (Berlin, Germany)
as part of the Nanosolutions EU project. The characterisa-
tion included measurements of the primary particle sizes,
the dispersion of the particles in ultrapure water as well as
in Krebs physiological saline, zeta potential in ultrapure
water, and dialysis experiments to assess any dissolution
of dissolved Cu from the particles. The CuO NPs were
first examined using transmission electron microscopy
(TEM, JEOL-1200EX II) for the primary particle size.
Fresh stock suspensions, at 100mg l− 1 nominal concen-
tration, were prepared in Milli-Q water and sub-samples
were examined visually with n = 60 measurements of par-
ticle diameter per sample (conducted manually using Ima-
geJ). The particle size distribution of the ENM in the
stock dispersions were also measured by nanoparticle
tracking analysis (NTA) using a Nanosight LM 10 (Mal-
vern Instruments, UK). Three sub-samples from each of
the fresh stock suspensions were vortexed for 10 s
immediately before analysis by NTA (Table 1). Zeta poten-
tial of CuO dispersions in ultrapure water (pH 5) was de-
termined by laser Doppler electrophoresis (Zetasizer
Nano ZS, Malvern Instruments, UK) as an average of five
separate measurements.
Dialysis experiments were conducted in Milli-Q water
at room temperature to measure the degree of copper
metal ion dissolution from all the ENM. Dialysis bags
were filled with 8 ml of the appropriate test suspension
at 100 mg l− 1 nominal concentration, and suspended in
a 600 ml beaker containing 492 ml of Milli-Q water (in
triplicate beakers). Samples of 1 ml were taken from the
external compartment of the beaker at time zero, 30
min, 1, 2, 3, 4, 6, 8 or 12 and 24 h for total Cu determin-
ation by ICP-OES or ICP-MS. The data were subse-
quently fitted to a rectangular hyperbola (using
SigmaPlot 13), and the maximum initial dissolution rate
calculated from the maximum slope.
Total copper concentrations
The total copper concentration in the samples of the ori-
ginal nanopowders were determined following aqua regia
digestion. In the case of water or saline samples from the
dialysis experiments, these were diluted in nitric acid.
Total Cu concentrations were determined by inductively
coupled plasma optical emission spectrophotometry (ICP-
OES, Thermo Scientific, iCAP 7000 Series), or equivalent
mass spectrophotometry (ICP-MS, Thermo Scientific, X
Series 2) as appropriate. The instrument detection limit
for the ICP-OES was 0.008mg l− 1 Cu and for the ICP-MS
was 0.003 μg l− 1 Cu. Briefly, samples were acidified,
matrix-matched to the ICP-OES/ICP-MS standard metal
solutions used for calibration, with 0.8mg l− 1 yttrium as
an internal standard. Sample blanks were included every
10 samples in each run of the instruments.
Dispersion preparation
CuO, CuO COOH and CuO NH3 were provided as
powders and CuO PEG as an aqueous suspension. At
the time of the study, it was not possible to calculate
equivalent molar doses of Cu because of uncertainty of
the stoichiometry and the technical challenges in meas-
uring the mass attributed to the coating. Thus, equiva-
lent mass of the whole material was used for dosing
[46]. Stock dispersions were prepared similarly as de-
scribed earlier [61]. Briefly, CuO powders were dispersed
in endotoxin-free water (HyClone Laboratories, Inc., Lo-
gan, UT) to a stock suspension of 1 mg/ml. The suspen-
sions were sonicated for 5 min by probe sonicator
(Branson Sonifier 250, Branson Ultrasonic Co., Danbury,
CT, USA) using a power output corresponding to a de-
livered power of 13W. 6.5% aqueous suspension of CuO
PEG was diluted 10x in endotoxin-free water to obtain a
stock dispersion of 6.5 mg/ml. Stock dispersion was
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sonicated for 2 min. Further dilutions of 50, 200 and
800 μg/ml (2.5, 10 and 40 μg/mouse, respectively) were
prepared in Dulbecco’s PBS (Gibco, Life Technologies,
Carlsbad, CA) with or without ovalbumin (OVA; Sigma-
Aldrich Co, St. Luis, MO) shortly after sonication and
used immediately for orophagyngeal aspirations.
Mice and sensitization
Female BALB/c mice (aged 6–8 weeks) were obtained from
Scanbur A/S (Karlslunde, Denmark) and quarantined for 1
week. The mice were housed in groups of four in transpar-
ent plastic cages bedded with aspen chip and were provided
standard mouse chow diet (Altromin no. 1314 FORTI,
Altromin Spezialfutter GmbH & Co., Germany) and tap
water ad libitum when not being treated. The environment
of the animal room was carefully controlled, with a 12 h
dark-light cycle, temperature of 20–21 °C, and relative hu-
midity of 40–45%. The experiments were performed in
agreement with the European Convention for the Protec-
tion of Vertebrate Animals Used for Experimental and
Other Scientific Purposes (Strasbourg March 18, 1986,
adopted in Finland May 31, 1990). All experiments were
approved by the State Provincial Office of Southern Finland
(ESAVI-3241-04.10.07-2013, permission number PH701A).
During the sensitization period, each mouse (eight per
group) received ip a mixture of 50 μg of OVA and 2mg
of aluminum/magnesium hydroxide (Alum; Imject®
Alum, Pierce Biotechnology, Rockford, IL) in 100 μl of
Dulbecco’s PBS on day 1 and 10. After 10-day recovery,
mice were exposed to 50 μl of Dulbecco’s PBS or 50 μg
of OVA in 50 μl of Dulbecco’s PBS with or without dis-
persed CuO materials via oropharyngeal aspiration in
isoflurane anaesthesia (Univentor 400 Anaesthesia Unit,
Abbott Laboratories, IL) on four consecutive days. CuO
materials were tested at three doses, 2.5, 10 and 40 μg/
mouse/administration. Mice were sacrificed using an
overdose of inhaled isoflurane 24 h after the last admin-
istration (Additional file 5: Figure S1).
Sample collection
Blood was collected from the vena cava (hepatic vein),
and the lungs were lavaged with Dulbecco’s PBS (800 μl
for 10 s) via the tracheal tube. The mouse chest was
opened, and half of the left pulmonary lobe was re-
moved, divided in two, stabilized in RNAlater® solution
(Life Technologies Ltd., Paisley, UK) and stored at −
70 °C for total RNA isolation and microarray analysis. A
part of the left lobe was embedded in Tissue-Tek®
O.C.T.™ compound (Sakura Finetek, Alphen aan Den
Rijn, The Netherlands), quick-frozen and stored at −
70 °C for immunohistochemical stainings. The rest of
the lungs were formalin-fixed, embedded in paraffin, cut,
affixed on slides, and stained with hematoxylin and eosin
(H&E) and periodic acid-Schiff (PAS) solutions.
BAL cell counts
100 μl of BAL samples were cytocentrifuged on slides at
1000 rpm for 10min (Miles Scientific Cyto-Tek centri-
fuge, Sakura Finetek). The slides were air-dried and
stained with May Grünwald-Giemsa (MGG). BAL cell
differentials (number of macrophages, neutrophils, eo-
sinophils and lymphocytes) were obtained as average
counts from three high-power fields (HPF). The cells
were counted at 50x under light microscopy (Leica DM
4000B; Leica, Wetzlar, Germany).
Lung histology
Recruitment of inflammatory cells into the lungs and mor-
phological alterations of the tissue were assessed after
H&E staining. The number of mucus-producing goblet
cells was determined after PAS-staining from three bron-
chi per mouse in control group and six bronchi per mouse
in treatment groups by counting PAS+ cells from 200 μm
of bronchus surface under light microscope.
Quantification of histological alterations was per-
formed by measuring all inflammatory areas and areas
including nuclear dust of one lung section per slide at a
total magnification of 100x with AxioVision V4.8.2 soft-
ware (Zeiss, Oberkochen, Germany). The results were
expressed as averages of the measured areas.
Immunohistochemistry
Immunoperoxidase staining was used to detect CD3+,
CD4+ and CD8+ lymphocytes in the lung tissue. Briefly,
4-μm frozen sections were fixed with cold acetone and
stained with anti-mouse CD3 antibody (Ab; clone 17A2),
anti-mouse CD4 Ab (clone RM4–5) and anti-mouse
CD8 Ab (clone 53–6.7). All primary Abs were purchased
from BD Biosciences Pharmingen (San Diego, Califor-
nia). Biotin-conjugated secondary Ab anti-rat IgG
(H + L) was purchased from Vector Laboratories.
Number of immunohistochemically stained positive
cells was counted under light microscopy at × 400
magnification from slides of five samples/group as
an average of three HPF/slide.
mRNA expression of cytokines in lung tissue
Lung samples were homogenized in 1 ml of TRIsure re-
agent (Bioline Reagents Ltd., London, UK) in Lysing
matrix D tubes (MP Biomedicals, Illkirch, France) with a
FastPrep FP120 machine (BIO 101, Thermo Savant,
Waltham, MA, USA). The RNA extraction was per-
formed following instructions provided by Bioline Re-
agents. The quantity and purity of isolated RNA was
determined by NanoDrop spectrophotometer (ND-1000,
Thermo Fisher Scientific Inc., Wilmington, NC, USA).
Complementary DNA (cDNA) was synthesized from
500 ng of total RNA in a 25 μl reaction using Multi-
Scribe Reverse Transcriptase and random primers (The
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High-Capacity cDNA Archive Kit, Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s
protocol. The synthesis was performed in a 2720 Ther-
mal Cycler (Applied Biosystems, Carlsbad, CA, USA)
starting at 25 °C for 10 min and continuing at 37 °C for
120 min. Primers and probes (18S ribosomal RNA, TNF,
IL-33, IL-13, CCL2, CCL7, CCL11) for PCR analysis
were ordered as pre-developed assay reagents from Ap-
plied Biosystems. The PCR assays were performed in 96-
well optical reaction plates with Relative Quantification
7500 Fast System (7500 Fast Real-Time PCR system, Ap-
plied Biosystems) by the manufacturer’s instructions.
Amplifications were done in 11 μl reaction volume con-
taining TaqMan universal PCR master mix and primers
provided by Applied Biosystems and 1 μl of cDNA sam-
ple. Ribosomal 18S was used as an endogenous control.
Cytokine levels in BAL supernatants
Protein secretion of IL-13 and CCL2 was measured in
BAL supernatants by commercial mouse uncoated
ELISA kits (Invitrogen, San Diego, CA). The assays were
performed according to the manufacturer’s instructions
and ELISA plate reader (Multiscan MS, Labsystems,
Finland) was used to record the absorbances.
DNA microarrays and statistical analysis of the data
Total RNA samples isolated from lung tissue as de-
scribed above were quantified and quality checked by
NanoDrop and Agilent Bioanalyzer 2100 (Agilent Tech-
nologies, Santa Clara, CA, USA), respectively. Samples
with RNA integrity number (RIN) > 8 were selected for
the analysis. Independent pools of two RNA samples
(total of 100 ng) were used to synthesize cDNA which
was transcribed to cRNA using T7 RNA polymerase
amplification method (Low Input Quick Amp Labeling
Kit, Agilent Technologies), according to the instructions
of the manufacturer. cRNAs were labeled with Cy3 and
Cy5 dyes (Agilent Technologies) and thereafter cleaned
up by using Qiagen’s RNeasy mini spin columns (Qia-
gen, GmbH, Hilden, Germany). 300 ng of a Cy3-labeled
sample and 300 ng of corresponding Cy5-labeled sample
were combined (total 600 ng). cRNA samples were frag-
mented and hybridized to the Agilent 2-color 60-mer
oligo arrays (Agilent SurePrint G3 Mouse Gene Expres-
sion v2 GE 8x60K). The slides were washed and scanned
with Agilent Microarray Scanner G2505C (Agilent Tech-
nologies) and the raw intensity values were obtained
with the Feature Extraction software, version 11.0.1.1
(Agilent Technologies). Raw data was quality checked
according to the Agilent standard procedures.
The median foreground intensities were imported into
the R software [62] and analyzed with limma package
within the BioConductor. Briefly, log2 transformation
and quantile normalization was performed.
Subsequently, batch effects derived from the labeling and
array-specific variance were removed using the ComBat
method [63] implemented in the sva package [64, 65]. The
same batches were taken also into account when limma
package [66] was used. The values of the probes recogniz-
ing the same NCBI Entrez Gene identifiers were further
averaged into the final expression matrix. The microarray
data is deposited in NCBI Gene Expression Omnibus
(GEO) database [67] and are accessible through GEO
Series accession number GSE122197 (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE122197). Differen-
tially expressed genes were identified by using linear
models and empirical Bayes pairwise comparisons (post
hoc adjusted P < 0.05 and linear fold change (FC) > |1.5|).
The resulting gene sets after Benjamini and Hochberg
post hoc correction [63] were considered to be significant
and were further studied.
Analysis tools
Enrichment analyses of biological processes were per-
formed using Enrichr [17, 18] and PANTHER [19] tools.
REVIGO [68] was used to summarize lists of gene ontol-
ogy (GO) terms. Canonical Pathway Analyses were carried
out through the use of IPA [16]. Unless otherwise specified,
the cut-off for a biological process or pathway to be con-
sidered significantly enriched was set at adjusted p value of
0.05. Bar and line plots were constructed using GraphPad
Prism 7 (GraphPad Software Inc., San Diego, CA, USA) or
IPA software. Heat maps and 2D scatter plots were created
with Perseus [69, 70], Venn diagrams with Venny 2.1.0
[71]. Tile plots were prepared by R software [62] using the
codes obtained from REVIGO tool [68].
Statistical analysis of cell counts and mRNA expression
levels
For statistical analysis of cell counts and PCR results, the
Analysis of Variance (ANOVA) was performed. Tukey
honest significant differences post-hoc testing was carried
out after ANOVA for selected pair-wise comparisons. A
P-value of < 0.05 was considered to be statistically signifi-
cant. Validation of microarray results by PCR was evalu-
ated with Pearson’s correlation test. The results were
considered accurate when Pearson’s r value was ~ 1.
Additional files
Additional file 1: Table S1. Total number of BAL cells and relative
portion of differential immune cells. The numbers are presented as mean
values ± standard error of mean (SEM). Statistically significant differences
of total cell numbers between experimental groups and PBS-challenged
control mice are marked with “*” whereas the ones between experimen-
tal groups and OVA-challenged control mice are marked with “•”.
***/•••P < 0.001. HPF, high power field; OVA, ovalbumin; PBS, phosphate
buffered saline. (TIF 1108 kb)
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Additional file 2: Table S2. Lists of the differentially expressed genes
from the microarray experiment. The tables with the differentially
expressed genes in each of the relevant pairwise comparisons (each
experimental group compared against corresponding PBS-challenged or
OVA-challenged controls) are reported in sheets of the Microsoft Excel
archive, named accordingly. In each table, the significantly differentially
expressed genes (Benjamini and Hochberg post hoc corrected P value <
0.05 and absolute log2 fold change > 0.58) are ordered according to the
decreasing log2 fold change. The Agilent probe IDs and gene symbols
are shown. Additionally, for each significant gene, the average expression
across the microarray samples, the t-test value, the nominal P value, the
adjusted P value and the B value are also reported. (XLSX 1842 kb)
Additional file 3: Table S3 Lists of the differentially expressed genes
from the microarray experiment. Experimental groups of PBS-challenged
or OVA-challenged mice that were treated with the same CuO material
were combined and compared against their corresponding controls. The
tables with the differentially expressed genes of each pairwise compari-
son are reported in sheets of the Microsoft Excel archive, named accord-
ingly. In each table, the significantly differentially expressed genes
(Benjamini and Hochberg post hoc corrected p-value < 0.05 and absolute
log2 fold change > 0.58) are ordered according to the decreasing log2
fold change. The Agilent probe IDs and gene symbols are shown. Add-
itionally, for each significant gene, the average expression across the
microarray samples, the t-test value, the nominal P value, the adjusted P
value and the B value are also reported. (XLSX 256 kb)
Additional file 4: Table S4. Lists of the differentially expressed genes
from the microarray experiment. Experimental groups treated with
modified CuO materials were compared against the groups treated with
the corresponding dose of core CuO in PBS-challenged or OVA-
challenged mice. The tables with the differentially expressed genes of
each pairwise comparison are reported in sheets of the Microsoft Excel
archive, named accordingly. In each table, the significantly differentially
expressed genes (Benjamini and Hochberg post hoc corrected p-value <
0.05 and absolute log2 fold change > 0.58) are ordered according to the
decreasing log2 fold change. The Agilent probe IDs and gene symbols
are shown. Additionally, for each significant gene, the average expression
across the microarray samples, the t-test value, the nominal P value, the
adjusted P value and the B value are also reported. (XLSX 338 kb)
Additional file 5: Figure S1. Murine model of allergic airway
inflammation. BALB/c mice were sensitized intraperitoneally (ip) with a
mixture of ovalbumin and aluminium/magnesium hydroxide (OVA/Alum)
on day 1 and 10. After a 10-day recovery period, 2.5, 10 or 40 μg/mouse
of CuO nanomaterials dispersed in PBS with or without OVA were admin-
istered repeatedly to mice by oropharyngeal aspiration on days 20–23.
Mice were sacrificed on day 24 for sample collection of bronchoalveolar
lavage fluid (BAL) and lung tissue. ENM, engineered nanomaterial; PBS,
phosphate buffered saline. (TIF 444 kb)
Additional file 6: Figure S2. Example transmission electron microscopy
images of engineered CuO nanoparticles in 100mg l− 1 Milli-Q water show-
ing, (A) uncoated CuO core, (B) CuO-COOH, (C) CuO-NH4
+ and, (D) CuO-PEG
NPs. The respective Nanosight graphs show the particle distribution (bin
sizes are hydrodynamic diameter) of the nanomaterials in 100mg l− 1 Milli-Q
water solutions. From Besinis and Handy, unpublished. (TIF 2186 kb)
Additional file 7: Figure S3. Example transmission electron microscopy
images of engineered CuO nanoparticles in 100 mg l− 1 Krebs
physiological saline showing, (A) uncoated CuO core, (B) CuO-COOH, (C)
CuO-NH4
+ and, (D) CuO-PEG NPs. The respective Nanosight graphs show
the particle distribution (bin sizes are hydrodynamic diameter) of the
nanomaterials in 100 mg l− 1 Milli-Q water solutions. From Besinis and
Handy, unpublished. (TIF 2625 kb)
Additional file 8: Figure S4. Dialysis curves showing the release of total
dissolved copper from uncoated CuO NPs core, CuO-COOH, CuO-NH4
+
and CuO-PEG NPs over a 24 h period when suspended in (A) Ultrapure
Milli-Q water, or (B) Krebs physiological saline. Controls are the respective
water or saline without nanomaterials. Data are means ± S.D., n = 3 repli-
cates. Curves were fitted using SigmaPlot 13.0 (Systat Software, Inc.) ap-
plying the single rectangular two parameter hyperbola equation on the
raw data. From Besinis and Handy, unpublished. (TIF 672 kb)
Additional file 9: Figure S5. Histological assessment of the lung tissue
after exposure to 10 μg/mouse of CuO nanomaterials. BALB/c mice were
sensitized ip to OVA/Alum on day 1 and 10, and exposed repeatedly to
10 μg/mouse of CuO nanomaterials dispersed in PBS with or without
OVA by oropharyngeal aspiration after a 10-day recovery period. A, H&E-
stained lung tissue of PBS- and OVA-challenged mice that were treated
with or without CuO nanomaterials. Histological changes were quantified
in selected experimental groups and the results were expressed as an
average size of inflammatory areas/section (B) and as an average size of
areas containing nuclear dust/section (C). Images (A) are shown at × 200
magnification with a 100-μm scale bar. Columns and error bars represent
mean values ± standard error of mean (SEM). *P < 0.05; **P < 0.01; ***P <
0.001. (TIF 6184 kb)
Additional file 10: Figure S6. Validation of microarray data by PCR and
ELISA. On the basis of the DNA microarray results, three genes were
selected for validation by PCR taking into account their biological
relevance in recruitment of leucocytes or in allergic airway inflammation.
PCR results confirmed an upregulation of monocyte-recruiting chemo-
kines CCL2 and CCL7 in lungs of ENM-treated mice compared with re-
spective control mice at both time points, and induction of and
eosinophil-attracting chemokine CCL11 in OVA-challenged mice. Micro-
array measurements were considered valid as the expression measured
by PCR was concordant with microarray data and the correlation be-
tween the results was significant. In addition, CCL2 was measured at pro-
tein level in BAL supernatants by ELISA and the results were highly
similar to those obtained by microarray and PCR. Left-sided plots present
microarray results, right-sided plots in the top panel and the middle plot
in the bottom panel express PCR results. Protein concentrations of CCL2
are presented in the bottom right. Data points and error bars represent
mean values ± standard error of mean (SEM). AU, arbitrary unit of fluores-
cence intensity; RU, relative expression unit. (TIF 1265 kb)
Additional file 11: Figure S7. Biomarkers associated to allergic airway
inflammation were found up-regulated in ovalbumin (OVA)-challenged
mice. Several markers known to play a role in asthma were chosen (pro-
allergic IL-33, Th2 type cytokine IL-4, eosinophil-attracting chemokines
CCL11 and CCL24, Th2 lymphocyte-attracting chemokine CCL17, and mu-
cins MUC5AC and MUC5B), and their microarray gene expression data
were compared in OVA-challenged and PBS-challenged mice. All selected
markers were significantly up-regulated in mice challenged with OVA in-
dicating that allergic airway inflammation developed in OVA-induced
mice. AU, arbitrary unit of fluorescence intensity; PBS, phosphate buffered
saline. (TIF 455 kb)
Additional file 12: Figure S8. General profiling of canonical pathways
and biological processes in OVA-challenged mice after CuO, CuO COOH
and CuO NH3 exposure. Experimental groups of exposed OVA-challenged
mice were merged based on the test material, and their transcriptomic
profiles were compared against the one of OVA-challenged controls. A,
Number of differentially expressed genes (DEGs; linear fold change (FC) >
|1.5|, adjusted P value < 0.05) in lungs of OVA-challenged mice exposed
to CuO nanomaterials by oropharyngeal aspiration (2.5, 10 and 40 μg/
mouse). B, Number of significantly enriched biological processes (ad-
justed P value < 0.05) obtained from analyses of DEG sets shown in (A),
and biological process enriched commonly by DEGs of CuO, CuO COOH
and CuO NH3 exposure with adjusted P values. (TIF 848 kb)
Additional file 13: Figure S9. DEGs with negative fold change in PBS
mice exposed to 2.5 μg of CuO PEG versus core CuO at the same dose
belong to processes related to inflammatory response. Treemap of GO
biological processes significantly enriched by down-regulated genes in
PBS-challenged mice exposed to 2.5 μg of CuO PEG compared against
core CuO at the same dose. The size of each rectangle reflects the false
discovery rate (FDR) of the corresponding GO term. GO terms are
grouped by semantic similarity (SimRel, similarity = 0.5) into the same
upper hierarchy term, visualized with different colours. (TIF 1139 kb)
Additional file 14: Figure S10. GO biological processes enriched by
DEGs in PBS mice exposed to 40 μg of CuO PEG versus core CuO at the
same dose belong to processes related to inflammatory response.
Treemap of GO biological processes significantly enriched by DEGs with
A) a positive fold change and B) a negative fold change. The size of each
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rectangle reflects the FDR of the corresponding GO term. GO terms are
grouped by semantic similarity (SimRel, similarity = 0.5) into the same
upper hierarchy term, visualized with different colours. (TIF 1880 kb)
Additional file 15: Figure S11. DEGs with a positive fold change in
OVA-challenged mice exposed to 40 μg of CuO PEG versus core CuO at
the same dose belong to processes related to inflammatory response.
Treemap of GO biological processes significantly enriched by up-
regulated genes in OVA-challenged mice exposed to 40 μg of CuO PEG
compared against core CuO at the same dose. The size of each rectangle
reflects FDR of the corresponding GO term. GO terms are grouped by se-
mantic similarity (SimRel, similarity = 0.5) into the same upper hierarchy
term, visualized with different colours. (TIF 732 kb)
Additional file 16: Figure S12. Number of DEGs and canonical
pathways involved in the inflammatory response to CuO materials in PBS-
challenged and OVA-challenged mice. A differential expression analysis was
performed in which each experimental group was compared against their
corresponding negative controls. Thereafter, the activation z-scores of the
pathways obtained from IPA were compared in PBS-challenged and OVA-
challenged mice. A, A table of DEG numbers specific to PBS- and OVA-
challenged groups, and an overlap between them (number of common
DEGs). B, A heatmap of (in)activation of predicted canonical pathways with
IPA cut-offs of absolute z-score > 2 and -log(P value) > 2. (TIF 1300 kb)
Additional file 17: Figure S13. Canonical pathways involved in the
inflammatory response to CuO materials. A differential expression analysis
was performed in which each experimental group was compared against
their respective PBS- or OVA-challenged control group. Activation z-scores of
the predicted pathways with cut-offs of absolute z-score > 2 and -log(P
value) > 2 were obtained from IPA and compared in PBS-challenged and
OVA-challenged mice. A-D, 2D-scatterplots of canonical pathways affected by
A) CuO, B) CuO COOH, C) CuO NH3 and D) CuO PEG exposure (40 μg/mouse)
in PBS- and OVA-challenged mice. Top 5 pathways of each section with the
highest z-scores have been denoted above or below the plot, and marked
on the plot with a filled circle. Blue circles refer to correlated and red to anti-
correlated pathways. Black circles indicate the pathways that had a z-score of
zero in one of the data sets. (TIF 1108 kb)
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